It is commonly used as a supplement by active people and those who want non-stimulant support for energy metabolism
however, gastrointestinal adverse effects such as nausea, vomiting, and diarrhea are the most frequently reported, particularly during the initial treatment phase (Wilding et al., 2021
Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients
These mirror the safety profile seen with GLP-1 receptor agonists broadly and are expected given the mechanism of action
GLP-1 drugs such as semaglutide , used for diabetes and obesity, are a more complicated case, because treatment failure and prevention promise point in opposite directions
BPC 157 is sold legally for research and laboratory use only